In accordance with this notion, anifrolumab, a monoclonal antibody to type I interferon (IFN-I) receptor subunit 1 (IFNAR1), has been shown to be promising in treating SLE by blocking the activation of IFN-I signaling pathway (2), which is critical to the pathogenesis of SLE and lupus nephritis (LN) (3). This evidence concerns the gene IFNAR1 and systemic lupus erythematosus.